Daniel Karlin Buys Shares of Definium Therapeutics

Daniel Karlin, the Chief Medical Officer of Definium Therapeutics, Inc. (NasdaqGS: DFTX), purchased 100,000 shares of the company on June 22, 2026. This transaction was not part of a planned trading program and occurred at an unspecified price.

Insider Buying and Selling at Definium Therapeutics, Inc.

In addition to Karlin, several other executives at Definium Therapeutics made notable stock purchases on June 22, 2026. Chief Legal Officer Mark Sullivan, Chief Financial Officer Brandi Roberts, Chief Executive Officer Robert Barrow, and Chief Commercial Officer Matthew Wiley each acquired 62,500 shares. CEO Robert Barrow made a more substantial buy of 375,000 shares. Andreas Krebs also added 19,188 shares to his holdings on June 11, 2026.

Other Institutional Activity in Definium Therapeutics

Several institutional investors have shown interest in Definium Therapeutics recently. BlackRock, Inc. opened a new position with 8,480,230 shares valued at approximately $160.3 million. Driehaus Capital Management LLC reduced its holdings by 625,313 shares, now holding 5,911,889 shares worth about $111.7 million, marking a 9.6% decrease. Avoro Capital Advisors LLC also opened a new position, acquiring 5,000,000 shares valued at $94.5 million. Similarly, Janus Henderson Group PLC and Deep Track Capital, LP initiated new positions with 3,556,041 shares and 3,000,000 shares, respectively.

Definium Therapeutics, Inc. Stock Down 10.5%

Shares of Definium Therapeutics traded near $24.48 on Monday. The company has a market cap of approximately $2.67 billion. Despite not being profitable, it has a forward P/E ratio of -15.48, indicating expectations of future profitability. The stock has shown volatility with a 52-week low of $6.35 and a high of $26.25. It maintains a beta of 2.378, indicating higher volatility compared to the market. The stock's 50-day moving average is $22.61, while the 200-day moving average stands at $16.28.

Analysts Set New Price Targets

Analysts have been actively covering Definium Therapeutics. On June 16, 2026, Canaccord Genuity maintained its buy rating with a $38.00 price target. Piper Sandler previously set a target of $48.00 on May 8, 2026. The consensus among 15 analysts is a strong buy, with a mean price target of $39.87.

About Definium Therapeutics

Definium Therapeutics, Inc. is a biopharmaceutical company based in New York, NY, focusing on brain health disorders. Its lead product, DT120, is in phase 3 trials for generalized anxiety disorder and major depressive disorder. Another candidate, DT402, is in phase 2a trials for autism spectrum disorder. The company, originally known as Mind Medicine (MindMed) Inc., rebranded in January 2026. Under the leadership of CEO Robert Barrow, Definium continues to innovate in the biotechnology sector.

Bottom Line

Daniel Karlin's recent purchase of Definium Therapeutics shares highlights insider confidence in the company's future. Investors often track such insider activity for insights into a company's prospects. As always, it's important to remember that insider transactions are backward-looking and may not reflect current sentiment.